The demonstration of the efficacy of ipilimumab (targeting CTLA-4) in metastatic melanoma (5) and its subsequent regulatory approval in 2011, led to a rapid expansion in the use of ICIs in immunooncology in a number of tumor indications and unprecedented tissue/site-agnostic authorization. This evidence concerns the gene CTLA4 and neoplasm.